Cannabis Law Report

OCTOBER 9, 2021

Further easing of laws relating to psychedelic mushrooms, possibly using the drug for mental health therapy and training Denver’s first responders to better react to a psychedelic crisis are just three of several recommendations issued in a new report by the Denver Psilocybin Mushroom Policy Review Panel. Read more at .

Decriminalization 52

Decriminalization Law Data Safety 52

Cannabis Law Report

DECEMBER 5, 2021

Revenue share payments will be based on North America sales of MDMA for use in MDMA-assisted therapy, will terminate after 8 years, and include a reciprocity payment structure that reduces payments once certain financial milestones are met.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

SpeedWeed

JULY 6, 2021

Harvard Law School is planning to open the first US policy center focused on the legalization and regulation of psychedelics like psilocybin, MDMA, and LSD. . Professor of Law at Harvard Law School. “By Harvard’s new center will be the first to focus solely on psychedelics policy and laws rather than research, though.

Policy 52

Policy Law Research and Development Therapy 52

NORML

MARCH 23, 2020

The National Organization for the Reform of Marijuana Laws wishes to reiterate its message that cannabis consumers and others beware of online misinformation surrounding the use of either whole-plant cannabis or CBD as a potential remedy for the COVID-19 virus. ”

CBD 342

CBD Therapy Treatment Packaging 342

MMJ Recs

JANUARY 20, 2024

With a nuanced approach to medical marijuana laws, the state has embarked on a journey that seeks to balance patient well-being, regulatory oversight, and societal concerns. Let’s take a closer look at medical marijuana laws in Maryland and how they affect those in need of MMJ treatment!

Law 52

Law Marijuana Patients Chronic Pain 52

Cannabis Law Report

FEBRUARY 28, 2022

Moreover, because Indigenous communities pioneered many aspects of modern psychedelic therapies, their patenting by Western corporations may promote biopiracy, the exploitation of Indigenous knowledge without compensation. MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study , 27 NATURE MED.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

NOVEMBER 4, 2021

Measure 109 requires the Advisory Board to give recommendations to OHA on the efficacy and safety of psilocybin therapy. The report found evidence that psilocybin therapy may be helpful in treating depression, anxiety, end-of-life issues, and addiction. Training Subcommittee Updates. You can contact Brett Mulligan at?

Law 52

Law Therapy Treatment Policy 52

MMJ Recs

JANUARY 2, 2024

Cannabis as a Complementary Therapy for Cancer Medical cannabis, also known as medical marijuana or MMJ, is increasingly recognized as a complementary therapy in the holistic approach to cancer care. Many individuals report improved symptom management and enhanced quality of life with its use, but experiences vary widely.

Treatment 98

Treatment Therapy Research and Development Patients 98

MMJ Recs

MAY 25, 2024

It makes cannabis therapy an option that would help a range of patients who suffer from several medical conditions, thanks to the modulation of the endocannabinoid system (ECS). Overall, by targeting the ECS, cannabis therapy offers a holistic approach to symptom relief for various medical conditions.

Patients 105

Patients Marijuana Cannabinoids Chronic Pain 105

Cannabis Law Report

MARCH 31, 2021

Meet the women who risked their credibility and safety to research psychedelic treatment and therapy long before they shared any… Read More.

Therapy 98

Therapy Safety Treatment 98

Cannabis Law Report

DECEMBER 14, 2021

During the Phase 1 trial, minimal adverse events were reported, and IGC-AD1 was tolerated with no safety concerns identified by an independent Data Safety Monitoring Board. The primary endpoint of our Phase 1 clinical trial was to test and demonstrate safety and tolerability. The average age was 80.9 In addition, 66.7%

Clinical Trials 52

Clinical Trials Safety Data Patients 52

MMJ Recs

MAY 9, 2024

Understanding State Laws: While medical marijuana is legal in many states, the specific regulations governing its use can vary widely. These organizations provide educational resources, assistance with navigating state laws, and support in obtaining medical marijuana cards.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Veriheal

JUNE 1, 2023

It had passed through the Senate and the Public Safety and Health committees, but the Assembly Appropriations Committee gutted its main provisions. SB 58, on the other hand, needed to pass through only the Public Safety and Health Committee, hence its accelerated progression to the floor. because there is no public hearing.”

Legalization 91

Legalization Decriminalization Legislation Therapy 91

Cannabis Law Report

DECEMBER 2, 2021

Recommendations and rulemaking relating to training and products were placed on an expedited timeline to ensure that facilitators will be trained, and products will be ready for the January 2, 2023, launch of the first state-sponsored psilocybin therapy program in the United States. Core Psilocybin Facilitation Skills (16 Hours).

Law 52

Law Programs Therapy Education 52

Cannabis Law Report

FEBRUARY 14, 2023

Marijuana Moment reports Arizona lawmakers have approved a bill in committee to promote research into the medical potential of psilocybin mushrooms for a variety of conditions, which could inform future reforms to more broadly allow access to psychedelic-assisted therapy. Kevin Payne (R), Jennifer […]

Therapy 52

Therapy Safety Legislation Conditions 52

Cannabis Law Report

FEBRUARY 14, 2020

Consumer products law blog. Class actions against CBD companies proliferate under federal and state law. Product testing and sampling protocols are not uniform across the country, and scientific data supporting the safety and efficacy of these products is under-developed. Plaintiffs claim damages in excess of $5 million.

State Laws 59

State Laws Law CBD Food 59

Cannabis Law Report

OCTOBER 13, 2021

But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. A Q&A with Mason Marks on new psychedelics law and regulation initiative. Psilocybin’s federal status as a Schedule I controlled substance is to blame.

Research and Development 52

Research and Development Therapy Access Data 52

MMJ Recs

NOVEMBER 17, 2023

Promoting Research and Innovation The medical marijuana industry promotes research and innovation in the field of cannabis-based therapies. Research and Innovation: Maryland’s MMJ program encourages research and innovation in the field of cannabis-based therapies, benefiting patients both in the state and nationwide.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

NOVEMBER 11, 2021

The initiative also created the Denver Psilocybin Policy Review Panel (“Panel”), which was required to report back to the City on the public safety and other impacts of decriminalization. There have been no significant negative impacts on public safety as a result of decriminalizing psilocybin possession in the City of Denver.

Policy 52

Policy Decriminalization Safety Therapy 52

Cannabis Law Report

JANUARY 12, 2022

According to a recent report released by the Psychedelic Science Funders Collaborative, “Oregon’s psilocybin therapy program provides a high-quality model for psychedelic healing in a non-prescription context that could be replicated in other states.”

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

MMJ Recs

MAY 29, 2024

In this comprehensive guide, we will explore the eligibility criteria, laws and regulations, steps to register for the medical marijuana card (MMJ), how to find a qualified physician and any other information involved in acquiring a medical marijuana card in Pennsylvania. Image by Iñaki del Olmo on Unsplash.

Marijuana 52

Marijuana Programs Patients Conditions 52

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

AUGUST 22, 2021

Biotech startup to bring safety and efficacy to the emerging psychedelic industry, brings on University of Michigan Researcher as Chief Science Officer. “The Janus particle technology has immense potential to transform the delivery of psychedelic therapies amid today’s mental health crisis. MIAMI , Aug.

Pharmaceutical 98

Pharmaceutical Medicine Research and Development Therapy 98

Cannabis Law Report

JANUARY 20, 2022

Robinson is Founding Partner of Mr. Cannabis Law – a full service law firm focused on the cannabis and psychedelic industries; Co-Founder of Mr. Psychedelic Law – a non-profit focused on psychedelic legal reform; and Managing Principal of Iter Investments – a venture capital firm deploying capital across the psychedelic ecosystem.

Therapy 52

Therapy Research and Development Access Events 52

Veriheal

AUGUST 24, 2022

Now, a psychedelic-focused bill aimed at reforming laws surrounding psychedelics further in the state has successfully qualified for the November ballot. In May 2022, Connecticut’s governor signed a budget bill that included a provision for the implementation of psychedelic-assisted therapy treatment centers. city to do so.

Legalization 108

Legalization Medicine Decriminalization Research and Development 108

MMJ Recs

MARCH 20, 2024

Furthermore, changes to testing and labeling requirements aim to uphold product quality and safety standards, providing patients with confidence in the products they receive from licensed dispensaries. Recent advancements include the expansion of qualifying medical conditions to ensure that more patients can benefit from cannabis therapy.

Dispensary 52

Dispensary Programs Access Patients 52

Cannabis Law Report

JUNE 14, 2022

Those values guide our joint efforts to change perceptions about psychedelic assisted therapies, raise awareness of the scientific advances and, ultimately, bring better health to European citizens. Ketamine is already registered for the treatment of depression and in 2023, the FDA might approve an MDMA assisted therapy for PTSD.

Access 52

Access Therapy Clinical Trials Treatment 52

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Canna Law Blog

FEBRUARY 24, 2020

Psilocybin has been in the news with increasing frequency as research into psychedelic therapy has proliferated, and a number of local jurisdictions, including the cities of Oakland, Denver , and Santa Cruz have decriminalized psilocybin to varying degrees. There is a possibility for local jurisdictions to “opt out.”.

Decriminalization 134

Decriminalization Therapy Research and Development Treatment 134

MMJ Recs

MARCH 6, 2024

From its historical origins to the present day, you’ll explore how attitudes, laws, and scientific advancements have shaped its acceptance. However, disparities between state and federal laws pose challenges, creating a complex regulatory landscape.

Marijuana 52

Marijuana Chronic Pain Patients Treatment 52

Veriheal

APRIL 11, 2022

federal law , it has not yet been used in any commonly prescribed medicines. The company initiated the first legal transfer (as deemed by federal law) to the U.S. I look forward to a time when they are not considered alternative therapies or home remedies but actually first-line therapies,” said the CEO of Zelira, Oludare Odumosu. “We

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

JULY 24, 2021

“The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

MMJ Recs

MARCH 2, 2024

Additionally, adhering to dispensary policies on product handling and consumption promotes harmony and safety. Ohio Cannabis Dispensary Regulations Dispensaries must adhere to strict regulations set forth by the Ohio Medical Marijuana Control Program to ensure compliance and patient safety.

Dispensary 52

Dispensary Patients Marijuana Education 52

Cannabis Law Report

JUNE 17, 2021

There are all-natural alternatives like CBD that may offer effective relief for mental health disorders, in addition to prescription medications and therapies. Finding the proper therapy combination might feel like an uphill battle, leaving people unhappy and in no better mental health. Is CBD effective in treating depression?

Oil 104

Oil CBD Therapy Treatment 104

MMJ Recs

JANUARY 24, 2024

Michigan marijuana laws and regulations Michigan’s marijuana laws and regulations reflect a progressive stance on cannabis, embodying a balanced approach that accommodates both medical and recreational use. The regulatory framework encompasses licensing, cultivation, and distribution, emphasizing safety and accountability.

Programs 52

Programs Marijuana Access Chronic Pain 52

Cannabis Law Report

OCTOBER 9, 2021

Indeed, studies conducted by world renowned medical institutions indicate that psilocybin has shown efficacy, tolerability, and safety in the treatment of conditions including but not limited to addiction, depression, anxiety disorders, and end-of-life psychological distress. Subject: REVISED – Public Health Benefits of Psilocybin Act.

Therapy 52

Therapy Clinical Trials Treatment Legislation 52

Cannabis Law Report

MAY 26, 2022

The OPEN Foundation invites you to the Interdisciplinary Conference on Psychedelic Research this September, featuring the world’s best experts on psychedelic science and therapy. So we need to discuss openly and critically how we can remain balanced and ensure the potential of psychedelics can be optimised without compromising safety.”.

Research and Development 52

Research and Development Therapy Policy Media 52